AN2 Therapeutics (ANTX) Accounts Payables (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Accounts Payables for 6 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 14.9% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 14.9% YoY), while the FY2025 annual figure was $3.0 million, down 8.92% from the prior year.
• Accounts Payables slipped to $2.6 million in Q1 2026 per ANTX's latest filing, from $3.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.9 million in Q3 2023 and bottomed at $1.4 million in Q3 2022.
• Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.6 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables surged 238.68% — and 2024, when it sank 64.92%.
• AN2 Therapeutics' Accounts Payables stood at $2.1 million in 2022, then rose by 26.11% to $2.7 million in 2023, then advanced by 23.95% to $3.3 million in 2024, then dropped by 8.92% to $3.0 million in 2025, then dropped by 13.44% to $2.6 million in 2026.
• Business Quant data shows ANTX's Accounts Payables at $2.6 million in Q1 2026, $3.0 million in Q4 2025, and $2.2 million in Q3 2025.